Drug
Bryostatin 1 clinical trials
- studies test it
- 42
- open now
- 0
- in phase 3
- 0
- first study started
- 1996
How studies write it
Studies that test it under each name
Name
- BRYO
- 9
Other names
Studies by the year they started
42 studies that test it; most in 1998 (9)
| Year | Studies |
|---|---|
| 1996 | 2 |
| 1997 | 4 |
| 1998 | 9 |
| 1999 | 5 |
| 2000 | 9 |
| 2001 | 3 |
| 2002 | 2 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2020 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 16
- Phase 2
- 27
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 39
National Cancer Institute (NCI) (11) · Barbara Ann Karmanos Cancer Institute (7) · Virginia Commonwealth University (4) · Neurotrope Bioscience, Inc. (3) · Memorial Sloan Kettering Cancer Center (3) · National Institute on Aging (NIA) (2) · University of Maryland, Baltimore (1) · Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal (1)
Often tested with
Tested in the same studies.
Paclitaxel (6) · Cisplatin (6) · Vincristine (3) · Cytarabine (2) · Rituximab (1) · Gemcitabine (1) · Cladribine (1) · Temsirolimus (1)
Studies
Open first, then newest update. How each study uses bryostatin 1 is read from its arms, and is right about nine times in ten.
Testing it · 42
- Safety of Bryostatin in Patients With MSTerminatedPhase 1Robert FoxNCT06190912Written as Bryostatin 1
- Bryostatin Treatment of Moderately Severe Alzheimer's DiseaseCompletedPhase 2Neurotrope Bioscience, Inc.NCT04538066Written as Bryostatin 1
- Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic CancerCompletedPhase 2National Cancer Institute (NCI)NCT00031694Written as bryostatin 1
- Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate CancerCompletedPhase 2University of Maryland, BaltimoreNCT00005028Written as bryostatin 1
- A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's DiseaseCompletedPhase 2Neurotrope Bioscience, Inc.NCT02431468Written as Bryostatin 1
- Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's DiseaseTerminatedPhase 1/2Neurotrope Bioscience, Inc.NCT02221947Written as Bryostatin 1
- Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral TreatmentCompletedPhase 1Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y CajalNCT02269605Written as Bryostatin 1 (10ug/m2)
- Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney CancerCompletedPhase 1Virginia Commonwealth UniversityNCT00006022Written as bryostatin 1
- Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedPhase 2National Institute on Aging (NIA)NCT00087425Written as bryostatin 1
- Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or LymphomaCompletedPhase 1National Institute on Aging (NIA)NCT00003993Written as bryostatin 1
- Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach CancerCompletedPhase 2National Cancer Institute (NCI)NCT00006389Written as bryostatin 1
- Bryostatin 1 Plus Gemcitabine in Treating Patients With Advanced CancerCompletedPhase 1Barbara Ann Karmanos Cancer InstituteNCT00004144Written as bryostatin 1
- Bryostatin 1 Plus Cladribine in Treating Patients With Relapsed Chronic Lymphocytic LeukemiaCompletedPhase 1Barbara Ann Karmanos Cancer InstituteNCT00003174Written as bryostatin 1
- Bryostatin 1 in Treating Patients With Recurrent or Refractory Hodgkin's DiseaseCompletedPhase 2Barbara Ann Karmanos Cancer InstituteNCT00003936Written as bryostatin 1
- Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedPhase 2National Cancer Institute (NCI)NCT00006942Written as bryostatin 1
- Cisplatin Plus Bryostatin 1 in Treating Patients With Advanced CancerCompletedPhase 1Lombardi Comprehensive Cancer CenterNCT00003108Written as bryostatin 1
- Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the CervixCompletedPhase 2Icahn School of Medicine at Mount SinaiNCT00005965Written as bryostatin 1
- Bryostatin 1 in Treating Patients With Ovarian Epithelial CancerCompletedPhase 2University of GlasgowNCT00004008Written as bryostatin 1
- Bryostatin 1 In Treating Patients With Progressive Kidney CancerCompletedPhase 2Cancer Research UKNCT00005056Written as bryostatin 1
- Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck CancerCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT00003443Written as bryostatin 1
Codes
What other systems call bryostatin 1 · ClinicalTrials.gg INT003238
- MeSH (NLM) C046785bryostatin 1Confirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 37O2X55Y9EBRYOSTATIN 1Confirmed FDA, NLM, Wikidata
- Wikidata Q27095907bryostatin 1Confirmed FDA, NLM, Wikidata
- NCI Thesaurus C1026Bryostatin 1One source FDA
- DrugBank DB11752One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C046785 | bryostatin 1 | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 37O2X55Y9E | BRYOSTATIN 1 | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27095907 | bryostatin 1 | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1026 | Bryostatin 1 | One source FDA |
| DrugBank | DB11752 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.